Open AccessDrivers of and Barriers to Adherence to Neovascular Age-Related Macular Degeneration and Diabetic Macular Edema Treatment Management Plans: A Multi-National Qualitative Study
Author(s) -
Audrey Giocanti-Aurégan,
Alfredo Garcı́a-Layana,
Tünde Petõ,
Brittany Gentile,
C Gloria,
Mirela Mirt,
Charlotte E Kosmas,
Jérémy Lambert,
Sally Lanar,
Heather Lewis,
Nancy M. Holekamp
Publication year - 2022
Publication title -
patient preference and adherence
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.885
H-Index - 48
ISSN - 1177-889X
DOI - 10.2147/ppa.s347713
Subject(s) - medicine , macular degeneration , diabetic macular edema , tolerability , ophthalmology , clinical trial , thematic analysis , diabetic retinopathy , diabetes mellitus , qualitative research , adverse effect , social science , sociology , endocrinology
Neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME) patients treated with intravitreally injected anti-vascular endothelial growth factor (anti-VEGF) monotherapies achieve lower vision improvements compared with patients in clinical trials. This qualitative research study aimed to better understand the real-world anti-VEGF treatment experience from nAMD and DME patients', caregivers', and retina specialists' perspectives.